ArticleSurgical case reports2026
A Case of Acquired Hemophilia A Following Robot-Assisted Minimally Invasive Esophagectomy.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcquired hemophilia A (AHA) is a rare but potentially fatal bleeding disorder that arises suddenly in individuals without a prior history of bleeding tendency. It is often associated with malignant disease and can present with severe hemorrhagic complications. Reports of AHA occurring in the postoperative course of esophageal cancer surgery are extremely limited, and the safety of immune checkpoint inhibitors (ICIs) in patients with a history of AHA remains uncertain. This case highlights both the diagnostic and therapeutic challenges of AHA and provides novel insight into the safe administration of ICIs in a patient with recurrent esophageal cancer following remission of AHA. CASE PRESENTATION: We describe a 77-year-old man with clinical stage II esophageal cancer who received neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil, followed by robot-assisted thoracoscopic and laparoscopic subtotal esophagectomy. Postoperatively, he developed an anastomotic stricture requiring re-anastomosis via median sternotomy. After the second surgery, he experienced uncontrollable wound bleeding, and laboratory testing revealed a markedly prolonged activated partial thromboplastin time. Further evaluation confirmed the diagnosis of AHA, for which medical therapy was initiated, resulting in remission. Subsequently, the patient developed recurrent esophageal cancer and is currently receiving fluorouracil plus cisplatin in combination with pembrolizumab. Notably, no relapse of AHA has been observed during immunotherapy.
conclusionsThis case illustrates that AHA can complicate the postoperative course of esophageal cancer surgery, leading to significant bleeding difficulties. It also suggests that ICIs may be administered relatively safely in patients with recurrent esophageal cancer who have previously developed AHA. Clinicians should remain vigilant for this rare but serious condition when encountering unexplained bleeding in cancer patients, and the findings may provide reassurance regarding the use of immunotherapy in similar clinical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.